Inventor · disambiguated record
Mitsunori Kato
Also filed as: KATO MITSUNORI
16 granted patents·4 pending applications·59 citations·filing 2011–2022
91Inventor score
Top patents by PatentIndex Score
20 records- 0192US10968235B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2019·Granted Apr 6, 2021·3 cites·3 claims
- 0292US10077276B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2015·Granted Sep 18, 2018·15 cites·22 claims
- 0390US10336774B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2018·Granted Jul 2, 2019·7 cites·22 claims
- 0490US10093646B21-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2015·Granted Oct 9, 2018·7 cites·10 claims
- 0590US9815813B21-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2CHEN ZHUOLIANG·Filed 2015·Granted Nov 14, 2017·13 cites·8 claims
- 0688US10301278B21-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2NOVARTIS AG·Filed 2017·Granted May 28, 2019·8 cites·7 claims
- 0781US10975080B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2016·Granted Apr 13, 2021·2 cites·3 claims
- 0877US2022073537A1N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 0976US8324239B2Furopyridine compounds and uses thereofBARNES DAVID·Filed 2011·Granted Dec 4, 2012·4 cites·10 claims
- 1075US11952386B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Apr 9, 2024·0 cites·12 claims
- 1175US2022348553A11-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of shp2NOVARTIS AG·Filed 2022·Application pending·0 cites
- 1274US12209098B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Jan 28, 2025·0 cites·26 claims
- 1369US11401259B21-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2NOVARTIS AG·Filed 2020·Granted Aug 2, 2022·0 cites·4 claims
- 1466US2021309663A1Compounds and compositions for inhbiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 1565US2022089597A1Compounds and compositions for inhbiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 1664US10774065B21-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2018·Granted Sep 15, 2020·0 cites·3 claims
- 1752US10550102B2Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activatorsNOVARTIS AG·Filed 2018·Granted Feb 4, 2020·0 cites·15 claims
- 1845US10208018B2Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activatorsADAMS CHRISTOPHER M·Filed 2015·Granted Feb 19, 2019·0 cites·18 claims
- 1932US9765067B2Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activatorsADAMS CHRISTOPHER M·Filed 2015·Granted Sep 19, 2017·0 cites·19 claims
- 2031US9957254B2Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activatorsADAMS CHRISTOPHER M·Filed 2015·Granted May 1, 2018·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Mitsunori Kato files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →